Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06386094
Status:
RECRUITING
Last Update Posted:
2024-04-26
First Post:
2023-09-19
Brief Title:
Cardiac Dysfunction in Patients With Non-alcoholic Fatty Liver Disease
Sponsor:
Post Graduate Institute of Medical Education and Research Chandigarh
Organization:
Post Graduate Institute of Medical Education and Research Chandigarh
Study Overview
Official Title:
Cardiac Dysfunction in Patients With Non-alcoholic Fatty Liver Disease
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress andor altered diastolic relaxation with electrophysiological abnormalities in absence of known cardiac disease Left ventricular diastolic dysfunction LVDD is associated with risk of hepatorenal syndrome HRS septic shock heart failure in the perioperative period following liver transplantation and after trans-jugular intrahepatic portosystemic shunt TIPS insertion The echocardiographic Ee ratio is a predictor of survival in LVDD with multiple studies including prospective data from our Centre The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease hypertensive heart disease cirrhotic cardiomyopathy which are contributors to overall cardiovascular risk of mortality
Detailed Description:
Nonalcoholic fatty liver disease NAFLD and heart failure HF are obesity-related conditions with high cardiovascular mortality Many new studies have linked NAFLD to changes in myocardial energy metabolism and to echocardiographic measurements of cardiac dysfunction especially heart failure with preserved ejection fraction Cardiac dysfunction in NAFLD is related to the release of inflammatory cytokines among those with steatohepatitis NASH However composite models looking at coronary artery disease systolic and diastolic heart failure and outcomes in patients with NAFLD are limited and the few preliminary analyses of this relationship using histologically-defined NASH or lean NAFLD remain unclear
In this project the investigators will screen patients with a diagnosis of non-alcoholic fatty liver disease for presence of coronary artery disease arrhythmias cirrhotic cardiomyopathy and develop a model for cardiac dysfunction in such patients
In this project the investigators will screen patients with a diagnosis of non-alcoholic fatty liver disease for presence of coronary artery disease arrhythmias cirrhotic cardiomyopathy and develop a model for cardiac dysfunction in such patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None